“By combining information about many patients from a collection of studies, our analysis determined that the more aggressive combination chemotherapy does not benefit older colon cancer patients as it does for those who are younger,” says Nadine Jackson McCleary, M.D., Ph.D., Dana-Farber gastrointestinal oncologist and the study’s lead author. Dr. Jackson McCleary received a 2008–2009 ASCO Young Investigator’s Award.
Adding oxaliplatin to chemotherapy treatment with 5FU reduces the risk of recurrence among patients less than 70 years old who have had their primary cancer removed, the study determined. This finding was expected, based on the results of previous individual trials. Patients under 70 who were treated with 5FU and oxaliplatin had improved disease-free survival, with the addition of oxaliplatin relatively reducing the risk of recurrence or death by approximately 15 percent. Patients 70 and older who were treated with the combined drug therapy, however, did not have improved outcomes, compared to patients who received 5FU alone.
“We found that adding chemotherapy agents to the standard 5FU regimen in older patients after surgery did not provide the benefits that younger patients see,” says Dan Sargent, Ph.D., of Mayo Clinic, a collaborator on the study. “For the older patient, this means that it is appropriate to choose the better tolerated treatment strategy of 5FU alone.”
The benefit of postsurgical treatment for both young and older colon cancer patients with 5FU was documented in a study authored by Dr. Sargent and colleagues in the New England Journal of Medicine in 2001. By 2003, however, oxaliplatin was approved for use in combination with 5FU, because the combination boosted the impact of 5FU on extending disease-free survival after colon cancer surgery. While the combined treatment carried additional risk of side effects, physicians prescribed the treatment strategy to patients of all ages. Initially, studies that examined age-related impact of the aggressive combination of chemotherapies did not indicate a difference in survival or recurrence related to patient age.
The current study being presented at the ASCO annual meeting includes a large enough patient base to powerfully discern differences related to age that are due to treatment regime.
“The younger patients do get an additional boost from both drugs used together,” Dr. Jackson McCleary notes. “Older patients don’t benefit from that combination of treatment.”
The findings arise from analysis of combined data collected within an expanded database by the Adjuvant Colon Cancer End Points (ACCENT) Group, a consortium of scientists. The ACCENT database includes data from more than 33,500 patients from the United States, Canada, Australia and Europe. ACCENT, chaired by Dr. Sargent, is supported by the North Central Cancer Treatment Group (NCCTG).
“At this point we can only speculate as to why older patients do not benefit from combined chemotherapies,” says Jeffrey Meyerhardt, M.D., M.P.H., of Dana-Farber and co-investigator on the trial. “We do know that a higher number of older patients have to stop the drug before completing the full six-month prescribed course of treatment.”
“These studies add to the knowledge base that defines how to choose treatment strategies for every individual patient,” Dr. Sargent says. “Age may become as important a consideration as tumor-specific factors when defining individual medical options for colorectal cancer patients.”
Approximately half of all colon cancer patients are older than 70. While about half of the colon cancer patients over 70 will live for five years, those with recurrence typically develop additional tumors within three years. The disease is diagnosed in a million people worldwide every year. In the United States, colorectal cancer accounts for 10 percent of new cancer cases, as well as 10 percent of cancer-related deaths every year.
Drs. Jackson McCleary, Meyerhardt, and Sargent conducted the analysis on the expanded database in concert with an international team of scientist participating in ACCENT, including Erin Green of Mayo Clinic; Greg Yothers, Ph.D., Biostatistical Center and University of Pittsburgh; Aimery de Gramont, M.D., Hôpital Saint-Antoine in Paris, France; Eric Van Cutsem, M.D., Ph.D., University of Leuven and Gasthuisberg University Hospital, Leuven, Belgium; Michael O’Connell, M.D., Mayo Clinic; Christopher Twelves, M.D., Cancer Research UK Clinical Centre, Leeds, United Kingdom; and Leonard Saltz, M.D., Weill Medical College of Cornell University and Sloan-Kettering Cancer Center.
ORLANDO — The combination of chemotherapies 5FU and oxaliplatin, compared to 5FU alone, decreases colon cancer recurrence after surgery and promotes longer survival for patients under 70 — but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists. They will present the study's findings Saturday, May 30, at the American Society of Clinical Oncology annual meeting in Orlando.
Share this Article
Related Content In Gastrointestinal Oncology
Treatment Options in BRAF-mutant Metastatic Colorectal Cancer
touchREVIEWS in Oncology & Haematology. 2022;18(2):103-6 DOI: https://doi.org/10.17925/OHR.2022.18.2.103
Until recently, treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor receptor (EGFR) monoclonal antibody, namely cetuximab and panitumumab, or an anti-angiogenic agent such as bevacizumab, aflibercept or ramucirumab. For subsequent lines of treatment, the tyrosine kinase inhibitor regorafenib is an important part of […]
Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers
touchREVIEWS in Oncology & Haematology. 2022;18(1):16–25 DOI: https://doi.org/10.17925/OHR.2022.18.1.16
Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1 In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 deaths, respectively, in 2022 alone.2,3 GEC is divided based on the histology of squamous […]
Cholangiocarcinoma: The Present and Future of Targeted Therapies
touchREVIEWS in Oncology & Haematology. 2022;18(1):9–15 DOI: https://doi.org/10.17925/OHR.2022.18.1.9
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1 CCAs tend to metastasize and have early lymph node involvement. As a result, only a small proportion of patients are considered for surgical management, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!